Protagen AG announced that it has entered into a long-term collaboration agreement with QIAGEN targeting the development of novel protein-based companion diagnostics for autoimmune disorders. Under the terms of the agreement, QIAGEN will gain access to the proprietary SeroTag® technology platform of Protagen, which enables the discovery and validation of novel protein-based marker panels. Such markers hold great promise for the development into companion diagnostics to guide treatment decisions in various autoimmune disorders. Financial details of the collaboration were not disclosed.